三超新材(300554.SZ):擬向各金融機構申請綜合授信額度總計不超8億元
格隆匯3月22日丨三超新材(300554.SZ)公佈,公司及全資子公司江蘇三超金剛石工具有限公司擬向各金融機構申請綜合授信額度總計不超過人民幣8億元,授信類型包括但不限於流動資金貸款、銀行承兑匯票、保函、國內信用證、國際信用證等,同時,以自有資產為上述融資提供抵押、質押等必要擔保。
適用期限為2019年年度股東大會審議通過之日起至重新核定綜合授信額度之日止,借款利率參照中國人民銀行規定的利率,由公司及子公司與借款銀行協商確定,並授權董事長在銀行綜合授信額度總額範圍內根據資金需求負責與銀行簽署相關協議及文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.